Compare BIO-TECHNE Corp (TECH) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United States Natural Gas Fund — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while United States Natural Gas Fund trades at $10.04. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while United States Natural Gas Fund pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| TECH | UNG | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Commodities - Energy |
52-Week High | $72.48 | $16.90 |
52-Week Low | $43.31 | $9.63 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
UNG trades at $10.46, down 0.95% with a bearish technical signal from moving averages. The ETF faces headwinds from high natural gas production and storage levels, though weather-driven demand provides some support. Recent EIA forecasts project record natural gas supply and demand through 2027, creating a mixed fundamental backdrop for this futures-based commodity ETF.
The outlook remains challenged by oversupply concerns, though long-term demand growth from LNG exports and data center power needs offers potential upside. Key risks include commodity price volatility and the structural limitations of futures-based ETFs versus equity-based alternatives like FCG.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
